What insurance policy changes affect code E80.21?

There are 3 tracked policy changes affecting code E80.21, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code E80.21?

Payers that have issued tracked updates for code E80.21 include: Aetna.

How do I get notified when code E80.21 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code E80.21. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code E80.21?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

E80.21 Insurance Policy Changes

ICD-10 E80.21 is officially defined as "Acute intermittent (hepatic) porphyria." code E80.21 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E80.21 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 18, 2026Medium impact
Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-10-14)
Aetna considers gonadotropin-releasing hormone (GnRH) analogs and antagonists medically necessary for commercial plan members only for the specific indications listed for each drug, including leuprolide, goserelin, histrelin, triptorelin, degarelix, cetrorelix and ganirelix, and treats all other indications as experimental, investigational or unproven. Each drug has separate criteria for initial approval and for continuation of therapy, and continuation for prostate cancer requires clinical benefit such as serum testosterone less than 50 ng/dL and no unacceptable toxicity. Precertification is required for the prostate cancer indication, and gender dysphoria treatment for members under 18 must be prescribed by or in consultation with a provider specialized in the care of transgender youth who has collaborated care with a mental health provider.
Aetna · Identified Aug 15, 2026Medium impact
Givosiran (Givlaari) (CPB 0961, reviewed 2026-01-09)
Aetna considers givosiran (Givlaari) medically necessary for acute hepatic porphyria (AHP) for commercial medical plans when the member is 18 years of age or older, is actively symptomatic or has had 4 or more porphyria attacks per year, and has an elevated urine porphobilinogen (PBG) or an elevated plasma or fecal porphyrin level. Continuation of therapy is considered medically necessary for members who are benefiting from it, such as through fewer porphyria attacks requiring hospitalization, urgent healthcare visits, or intravenous hemin. Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-07-10)
Aetna covers gonadotropin-releasing hormone (GnRH) analogs and antagonists under its commercial medical plans for the indications the policy lists, including prostate cancer, breast cancer, ovarian cancer, central precocious puberty, endometriosis, uterine leiomyomata (fibroids), and ovulation induction or assisted reproductive technology. The policy also sets criteria for gender dysphoria treatment, including pubertal suppression in adolescents and gender transition, and for continuation of therapy. Aetna considers all other indications experimental, investigational, or unproven.

Watch E80.21

Get one email when a payer policy names E80.21, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-10-14)

Givosiran (Givlaari) (CPB 0961, reviewed 2026-01-09)

Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-07-10)

What insurance policy changes affect code E80.21?

Which payers have updated policy for code E80.21?

How do I get notified when code E80.21 policy changes?

Why do payers change policies for code E80.21?